Adjuvant Immunotherapy Should not be Used for Early-Stage Non-Small Cell Lung Cancer Patients Achieving a Complete Pathological Response Post Neoadjuvant Chemo-Immunotherapy

ZHANG Xiao-long; PU qiang

doi:10.12019/j.issn.1671-5144.202403011

ZHANG Xiao-long, PU qiang. Adjuvant Immunotherapy Should not be Used for Early-Stage Non-Small Cell Lung Cancer Patients Achieving a Complete Pathological Response Post Neoadjuvant Chemo-Immunotherapy[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 142-144. DOI: 10.12019/j.issn.1671-5144.202403011

Citation:

ZHANG Xiao-long, PU qiang. Adjuvant Immunotherapy Should not be Used for Early-Stage Non-Small Cell Lung Cancer Patients Achieving a Complete Pathological Response Post Neoadjuvant Chemo-Immunotherapy[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 142-144. DOI: 10.12019/j.issn.1671-5144.202403011

Citation:

ZHANG Xiao-long, PU qiang. Adjuvant Immunotherapy Should not be Used for Early-Stage Non-Small Cell Lung Cancer Patients Achieving a Complete Pathological Response Post Neoadjuvant Chemo-Immunotherapy[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 142-144. DOI: 10.12019/j.issn.1671-5144.202403011

Adjuvant Immunotherapy Should not be Used for Early-Stage Non-Small Cell Lung Cancer Patients Achieving a Complete Pathological Response Post Neoadjuvant Chemo-Immunotherapy

Graphical Abstract

Abstract

FullText(HTML)

References (9)

Adjuvant Immunotherapy Should not be Used for Early-Stage Non-Small Cell Lung Cancer Patients Achieving a Complete Pathological Response Post Neoadjuvant Chemo-Immunotherapy

Catalog

Export File

Citation

Format

Content